“Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in the Phase 3 Clinical Trials in Psoriasis, POETYK PSO-1 and PSO-2: Time to Meaningful Improvements in Itch As Assessed by the Psoriasis Symptoms and Signs Diary”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 2, Mar. 2024, p. s358, https://doi.org/10.25251/skin.8.supp.358.